Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 2, 2012, Pages 184-190

  Nordmann, Sandra ^a,b   Frauger, Elisabeth ^a,b   Pauly, Vanessa ^c   Orléans, Veronica ^c   Pradel, Vincent ^c   Mallaret, Michel ^d   Thirion, Xavier ^c   Micallef, Joëlle ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Buprenorphine; Generic form; Opioid maintenance treatment; OPPIDUM survey; Post marketing surveillance

Indexed keywords

BUPRENORPHINE; COCAINE; DIAMORPHINE; GENERIC DRUG; OPIATE;

ADULT; ALCOHOLISM; ARTICLE; COCAINE DEPENDENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MISUSE; DRUG SURVEILLANCE PROGRAM; EDUCATIONAL STATUS; FEMALE; GROUPS BY AGE; HEROIN DEPENDENCE; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OCCUPATION; PRIORITY JOURNAL; SUBSTANCE ABUSE;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; FRANCE; HUMANS; MALE; MULTIVARIATE ANALYSIS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; REGRESSION ANALYSIS; SUBSTANCE ABUSE TREATMENT CENTERS; YOUNG ADULT;

EID: 84856288236     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2263     Document Type: Article

References (39)

1. Bilal S, Menares J, De La Selle P, et al. Effect of maintenance treatments on social life. A study with general practitioners. Ann Med Interne 2003; 154(2): S6-S14.
2. Lapeyre-Mestre M, Llau ME, Gony M, et al. Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users. Drug Alcohol Depend 2003; 72(3): 297-303.
3. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285(1): 45.
4. Duburcq A, Charpak Y, Blin P, et al. Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex). Rev Epidemiol Sante Publique 2000; 48(4): 363-373.
5. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 2007; 9(5): 358-364.
6. Escots S, Fahet G, Usages non substitutif de la buprénorphine haut dosage en France. Graphiti - ORSMIP 2004 - OFDT.
7. a. Roux P, Villes V, Bry D, et al. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict Behav 2008; 33(12): 1625-1629.
8. b. Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008; 97(1-2): 105-113.
9. Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104(1-2): 73-77.
10. Reynaud M, Petit G, Potard D, et al. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93(9): 1385-1392.
11. Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22(6): 430-434.
12. Mégarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev 2006; 25(2): 79-85.
13. Journal Officiel de la République Française. Arrêté du 7 novembre 2008 portant approbation de l'avenant n° 3 à l'accord national relatif à la fixation d'objectifs de délivrance de spécialités génériques. n°0268 du 18 novembre 2008; pp. 17601.
14. Shlomi D, Shitrit D, Bendayan D, et al. Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug. Int J Chron Obstruct Pulmon Dis 2008; 3(2): 327-330.
15. Gross EM, Talc embolism: sudden death following intravenous injection of phenyltoloxamine, Forensic Sci Int 1973; 475-480.
16. Dettmeyer RB, Verhoff MA, Brückel B, et al. Widespread pulmonary granulomatosis following long time intravenous drug abuse--a case report. Forensic Sci Int 2010; Apr 15; 197(1-3): 27-30.
17. Potier A, Leclech C, Croue A, et al. Necrotic livedo after injection of buprenorphine (Subutex). Ann Dermatol Venereol 2007; Feb; 134(2): 148-150.
18. Andresz V, Marcantoni N, Binder F, et al. Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis. Addiction 2006; Sep; 101(9): 1347-1351.
19. El-Haik Y, Frauger E, Tanti-Hardouin N, et al. Use of generic High Dose Buprenorphine (HDB): about a qualitative survey. Fundam Clin Pharmacol 2011; 25(69): 1-111.
20. Cicero TJ, Inciardi JA, Surratt H. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug Alcohol Depend 2007; 91(2-3): 115-120.
21. Inciardi JA, Cicero TJ, Munoz A, et al. The Diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis 2006; 25(2): 53-58.
22. Cicero TJ, Inciardi JA, Adams EH, et al. Rates of abuse of tramadol remain unchanged with the introduction of new brand and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf 2005; 14(12): 851-859.
23. Canarelli T, Coquelin A, OFDT. Données récentes relatives aux traitements de substitution aux opiacés. Tendances n° 65 2009, OFDT, 6 p.
24. Micallef J, Lapeyre-Mestre M. Second Meeting of the French CEIP (Centres d'Évaluation et d'Information sur la Pharmacodépendance). Part I: How to Evaluate and Prevent the Abuse and Dependence on Hypnotic/Anxiolytic Drugs? Therapie 2009; 64(6): 355-364.
25. Boulos M, Arditti J, Pépin G et al. DRAMES: studies results (2002-2006). Le courrier des addictions, 2008; (10) n°1.
26. Frauger E, Vigneau C, Orléans V, et al. Consumption of cannabis among subjects with history of abuse/dependence or under an opiate maintenance therapy: OPPIDUM data in 2006 and main trends since 2004. Therapie 2008; Mar-Apr; 63(2): 119-127.
27. Djezzar S, Questel F, Burin E, et al. Chemical submission: results of 4-year French inquiry. Int J Legal Med 2009; 123(3): 213-219.
28. Boeuf O, Lapeyre-Mestre M; French Network of Centers for Evaluation and Information Pharmacodependence (CEIP). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf 2007; 30(3): 265-276.
29. Thirion X, Micallef J, Barrau K, et al. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Eur Addict Res 2001; 7(1): 32-36.
30. Barrau K, Thirion X, Micallef J et al. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction 2001; 96: 1433-1441.
31. Sapone A, Canistro D, Bonamassa B, et al. Hidden paradoxes in generic drug substitution affecting pharmacotherapy. J Biomed Biotechnol 2009; 2009: 801984.
32. Waber RL, Shiv B, Carmon Z, et al. Commercial features of placebo and therapeutic efficacy. JAMA 2008; 299(9): 1016-1017.
33. Rao AR, Monroe KB. The effect of price, brand name, and store name on buyers' perceptions of product quality: an integrative review. J Mark Res 1989; 26(7): 351-357.
34. Inciardi JA, Surratt HL, Stivers Y, et al. FDA approvals of generic drugs: Impact on the diversion of opioid analgesics with a potential for abuse. J Opioid Manag 2009; 5(2): 81-87.
35. Bailey JE, Barton PL, Lezotte D, et al. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. Drug Alcohol Depend 2006; 84(2): 182-187.
36. Pradel V, Frauger E, Thirion X, et al. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18(1): 36-43.
37. Harrison L. The validity of self-reported drug use in survey research: an overview and critique of research methods. NIDA Res Monogr 1997; 167: 17-36.
38. Dart RC. Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend 2009; 105 Suppl 1: S26-S32.
39. Harroche J, Moracchini C, Pradel V, et al. Health status of patients under opioid maintenance therapy followed by general practitioners. Fundam Clin Pharmacol 2011; 25(69): 1-111.